The winners and losers from JPM 2019

This year's J.P. Morgan Healthcare Conference proved to be a salve for biotech's recent woes.

Fueled by two major buyouts, shares in most drugmakers rose over the course of the four-day meeting, reversing a stock slide that weighed down the sector in the waning months of 2018.